Delayed vomiting is a potentially significant adverse effect of chemotherapy used to treat childhood cancer, but little is known about the experience of delayed vomiting in children and adolescents. An exploratory study was conducted to determine the pattern of delayed vomiting in children and adolescents with cancer after highly emetic chemotherapy and to identify possible risk factors. In a sample of 82 children and adolescents who completed 117 cycles of highly emetic chemotherapy, the overall prevalence of delayed vomiting was 32%. The frequency of delayed vomiting was highest on delayed day 2, with 21% of participants experiencing vomiting. By delayed day 7, only 9% of participants still reported vomiting. The severity of vomiting was moderate to severe in 11% to 12% of subjects. Age and gender had no significant effect on delayed vomiting. The emetic potential of the agent, incomplete protection from acute vomiting, and treatment regimens that lasted 6 or more days significantly affected delayed vomiting. In addition, a history of motion sickness, lack of acute control, and 6 or more days of chemotherapy were predictive of delayed vomiting.
American Society of Hospital Pharmacists (ASHP). (1999). Therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health-Systems Pharmacy, 56, 729-764.
2.
Bergkvist, K., & Wengstrom, Y. (2006). Symptom experiences during chemotherapy treatment with focus on nausea and vomiting. European Journal of Oncology Nursing, 10, 21-29.
3.
Carey, M. P., & Burish, T. G. (1988). Etiology and treatment of the psychological effects associated with cancer chemotherapy: A critical review and discussion. Psychological Bulletin, 104, 307-325.
4.
Children’s Oncology Group. (2005). Childhood cancer statistics. Retrieved July 18, 2006, from www.CureSearch.org
5.
Culy, C. R., Bhana, N., & Plosker, G. L. (2001). Ondansetron: A review of its use as an anti-emetic in children. Pediatric Drugs, 3, 441-479.
6.
Dupuis, L. L., Lau, R., & Greenberg, M. L. (2001). Delayed nausea and vomiting in children receiving antineoplastics. Medical and Pediatric Oncology, 37, 115-121.
7.
Fromer, M. J. (2005). Chemotherapy-induced nausea and vomiting: Research update on improving control. Oncology Times, 1, 21-23.
8.
Gralla, R. J., Osoba, D., Kris, M. G., Kirkbride, P., Hesketh, P. J., Chinnery, L. W., et al. (1999). Recommendations for the use of anti-emetics: Evidence-based, clinical practice guidelines. Journal of Clinical Oncology, 17, 2971-2994.
9.
Greenberg, D. B., Kornblith, A. B., Herndon, J. E., Zuckerman, E., Schiffer, C. A., Weiss, R. B., et al. (1997). Quality of life for adult leukemia survivors treated on clinical trials of Cancer and Leukemia Group B during the period of 1971- 1988: Predictors for later psychological distress. Cancer, 80, 1936-1944.
10.
Hesketh, P. J., Grunberg, S. M., Gralla, R. J., Warr, D. G., Roila, F., deWit, R., et al. (2003). The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin. Journal of Clinical Oncology, 21, 4112-4119.
11.
Hockenberry, M. (2004). Symptom management research in children with cancer. Journal of Pediatric Oncology Nursing, 21, 132-136.
12.
Holdsworth, M. T., Raisch, D. W., & Frost, J. (2006). Acute and delayed emesis control in pediatric oncology patients. Cancer, 4, 931-940.
13.
Kris, M. G., Gralla, R. J., Clark, R. A., Tyson, L. B., O’Connell, J. P., Wertheim, M. S., et al. (1985). Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. Journal of Clinical Oncology, 3, 1379-1384.
14.
LeBaron, S., Zeltzer, L. K., LeBaron, C., Scott, S. E., & Zeltzer, P. M. (1988). Chemotherapy side effects in pediatric oncology patients: Drugs, age and sex as risk factors. Medical and Pediatric Oncology, 16, 263-268.
15.
Li-Hua, L., & Hayman, L. L. (1999). Parents associated with children in measuring acute and delayed nausea and vomiting. Nursing and Health Sciences, 1, 155-161.
16.
McCaffrey, C. N. (2006). Major stressors and their effects on the well-being of children with cancer. Journal of Pediatric Nursing, 21, 59-66.
17.
Morrow, G. R. (1996). Frequency and clinical implications of delayed nausea and emesis. American Journal of Clinical Oncology, 19, 199-203.
18.
National Cancer Institute (NCI). (1999). Common toxicity criteria, version 2.0 [Software]. Bethesda, MD: Author.
19.
Rhodes, V. A., Watson, P. M., & Johnson, M. H. (1984). Development of reliable and valid measures of nausea and vomiting. Cancer Nursing, 2, 33-41.
20.
Roila, F., Boschetti, E., Tonato, M., Basurto, C., Bracarda, S., Picciafuoco, M., et al. (1991). Predictive factors of delayed emesis in cisplatin-treated patients and anti-emetic activity and tolerability of metoclopramide or dexamethasone. American Journal of Clinical Oncology, 14, 238-242.
21.
Roila, F., Donati, D., Tamberi, S., & Margutti, G. (2002). Delayed emesis: Incidence, pattern, prognostic factors, and optimal treatment. Supportive Care in Cancer, 10, 88-95.
22.
Taketoma, C. K., Hodding, J. H., & Kraus, D. M. (2005). Pediatric drug dosage handbook (11th ed.). Hudson, OH: Lexi-comp.
23.
Tyc, V. L., Mulhern, R. K., Fairclough, D., Ward, P. M., Relling, M. V., & Longmire, W. (1993). Chemotherapy induced nausea and emesis in pediatric cancer patients: External validity of child and parent emesis ratings. Developmental and Behavioral Pediatrics, 14, 236-241.
24.
Warr, D. G., Grunberg, S. M., Gralla, R. J., Hesketh, P. J., Roila, F., Wit, R., et al. (2005). The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomized, double-blind, placebo-controlled trials. European Journal of Cancer, 41, 1278-1285.
25.
Watson, M., McCarron, J., & Law, M. (1992). Anticipatory nausea and emesis, and psychological morbidity: Assessment of prevalence among outpatients on mild to moderate chemotherapy regimens. British Journal of Cancer, 66, 862-866.
26.
Zeltzer, L. K., Richie, D. M., LeBaron, S., Reed, D., Schoolfield, J., & Prihoda, T. J. (1988). Can children understand and use a rating scale to quantify somatic symptoms? Assessment of nausea and vomiting as a model. Journal of Consulting and Clinical Psychology, 56, 567-572.
